CHCWM – Cancer & Hematology Centers of West Michigan

In the News

As the largest physician-owned oncology and hematology practice in Michigan, we are often in the news. See what we've been up to.
CHC’s Dr. Amy Vander Woude discusses metastatic breast cancer on WZZM 13

Cancer & Hematology Centers of Western Michigan (CHC)’s Amy Vander Woude, MD, was recently featured on WZZM 13, discussing metastatic breast cancer and START Midwest. To watch the full interview, click here.   Read more »


CHC COVID protocols will remain unchanged amidst Michigan rulings

At Cancer & Hematology Centers of Western Michigan (CHC), Rheumatology Centers of Western Michigan (RCWM) and START Midwest, we are dedicated to the safety and health of our patients and staff. That is why we’ve closely reviewed the Michigan Supreme Read more »


CHCWM named one of Nation’s Best and Brightest Companies to Work For® for third year in a row

Cancer and Hematology Centers of Western Michigan (CHCWM) has been named one of the Nation’s Best and Brightest Companies to Work For® for the third year in a row. Organizations were chosen based on the assessment of various categories, including Read more »


Join our LLS Light the Night Team!

The Leukemia & Lymphoma Society (LLS)’s Light the Night Fundraiser is next week Thursday, Oct. 1, and we would love for patients and families to join the CHCWM team! This year’s event is virtual, and while this may have its »


START Midwest physicians present at Virtual ESMO Congress

START Midwest’s Nehal Lakhani, MD, PhD, and Manish Sharma, MD, were granted oral presentations at the European Society for Medical Oncology (ESMO)’s Virtual 2020 Congress. The physicians’ presentations were two of the four “Investigational Immunotherapy” presentations selected to be shared. »


START Midwest physician published in ‘New England Journal of Medicine’

START Midwest physician Nehal Lakhani, MD, PhD, authored an article that was recently published on The New England Journal of Medicine’s website. The article titled “The Efficacy of Selpercatinib in RET-Altered Thyroid Cancers” details START Midwest’s former LIBRETTO-001 clinical trial, Read more »


Page 1 of 8
Page: